Global Thermostable Vaccines and Thermostable Biologics Market to 2035 – by Type of Molecule, Target Indications, Type of Therapy, Key Players and Region – ResearchAndMarkets.com

Yahoo-Finance

DUBLIN, February 08, 2022–(BUSINESS WIRE)–The “Thermostable Vaccines and Thermostable Biologics Market by Type of Molecule, Target Indications, Type of Therapy, Key Players, and Key Geographical Regions: Industry Trends and Global Forecasts, 2021-2035” report has been added to ResearchAndMarkets.com’s offering.

This report features an extensive study of the current market landscape and future opportunities for the players involved in the development of thermostable vaccines and biologics for the treatment of a variety of disease conditions. The study presents an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain, across different geographies.

Read Full Article->

Recent News

Esperovax Awarded Subcontract for Development of Thermostable Oral Vaccine Platform

December 12, 2024

Esperovax Awarded $1M for Development of an Oral COVID-19 RNA Vaccine under the HHS Project NextGen Initiative 

August 23, 2023

Esperovax Appoints Dr. Robin Robinson as President and CEO

April 29, 2023

Esperovax, Ginkgo Bioworks Join Hands To Develop Circular RNA-based Therapeutics

January 10, 2023

Esperovax Signs Exclusive Licensing Agreement with the University of Michigan for a Novel Manufacturing Technology for the Production of Vaccines and Therapeutics

November 30, 2022

Esperovax and Life Magnetics to Deliver New Oral Therapeutic to Colorectal Patients

August 1, 2022

Esperovax Selected as a
BLUE KNIGHT™ Company

February 14, 2022

Esperovax Co-Founders Published in Separation and Purification Technology Journal

May 15, 2021

Michigan Rise Invests in Esperovax

April 29, 2021

The Sleeping Giants of Vaccine Production Awaken

February 3, 2021